[Sudden deafness: a randomized comparative study of 2 administration modalities of hyperbaric oxygenotherapy combined with naftidrofuryl].
Hyperbaric oxygen therapy is one of the numerous therapies which have been proposed in the management of sudden deafness. It is presumptuous to claim the efficiency of any treatment in a pathology where both the origin and the actual rate of spontaneous recovery are unknown. The grounds of therapies are therefore empirical but the need of urgent therapy is dictated by ethics. This study compares the effects of hyperbaric oxygen therapy in two groups of patients; according ot their order in randomization the subjects were treated either at a rate of 1 session or 2 sessions per day. Hyperbaric oxygen therapy was associated with infusion of Naftidrofuryl to counteract the vasoconstrictive effect of increased oxygen pressure in blood. Steroids were also administered simultaneously to avoid, for the same reasons, cerebral oedema. Normovolemic hemodilution (Dauman et al. 1983) was systemically performed in all the patients preliminarily to hyperbaric oxygen therapy, in order to reduce the haematocrit and thus facilitate blood supply. The efficiency and the side effects were similar in the two groups, provided that some principles in the selection and the monitoring of the patients were respected. The rate of 2 sessions of hyperbaric oxygen therapy per day has obvious advantages in view of health policy, but it requires the hospitalization of the patient and should be restricted to the younger subjects.
Dauman
R
R
C.H.U. Bordeaux, Hôpital Pellegrin, Service ORL, France.
Poisot
D
D
Cros
A M
AM
Zennaro
O
O
Bertrand
B
B
Duclos
J Y
JY
Esteben
D
D
Milacic
M
M
Boudey
C
C
Bébéar
J P
JP
D000328:Adult; D001299:Audiometry; D002985:Clinical Protocols; D003639:Hearing Loss, Sudden / Q000628:therapy*; D006438:Hemodilution / Q000379:methods; D006801:Humans; D006931:Hyperbaric Oxygenation; D008875:Middle Aged; D009257:Nafronyl / Q000627:therapeutic use*
D009257:Nafronyl
Surdités brusques: étude comparative randomisée de deux modes d'administration de l'oxygénothérapie hyperbare associée au Naftidrofuryl.